# AZD7789

Source: https://onco.cc/drugs/azd7789/  
OnCo record `azd7789` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

AZD7789 is an experimental bispecific antibody from AstraZeneca in phase 2 trials for non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer, aimed at PD-1 and TIM-3.

## Summary

AZD7789 is a bispecific antibody developed by AstraZeneca. Its targets are PD-1 and TIM-3 (the sponsor names PD-1 x TIM-3). The sponsor states: An anti-PD-1 and anti-TIM-3 bispecific antibody that simultaneously engages both immune checkpoints to enhance anti-tumour immunity. ClinicalTrials.gov describes the intervention as: anti-PD-1 and anti-TIM-3 bispecific antibody. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in non-small-cell lung cancer and gastric & gastro-oesophageal junction cancer. The largest, NCT04931654, plans to enrol 136 participants (actual) with primary completion was scheduled for 2024-12-04 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: bispecific antibody
- Mechanism: An anti-PD-1 and anti-TIM-3 bispecific antibody that simultaneously engages both immune checkpoints to enhance anti-tumour immunity.

## Sources

- ClinicalTrials.gov: trials of AZD7789: https://clinicaltrials.gov/search?intr=AZD7789

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [PD-L1-high gastric cancer](https://onco.cc/cancers/gastric-pdl1-high/)
- targets: [PD-1](https://onco.cc/targets/pd1/), [TIM-3](https://onco.cc/targets/tim3/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)
- trials: [A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer](https://onco.cc/trials/nct04931654/)

---
JSON: https://onco.cc/api/v1/entities/azd7789.json